Generic Products News

Pharmacy Times, February 2020, Volume 87, Issue 2

This month's generic products feature oral suspension for hypertension, peroxide gel, and more.

SILDENAFIL CITRATE FOR ORAL SUSPENSION

MARKETED BY: Amneal Pharmaceuticals

COMPARE TO: Revatio

The FDA has approved a generic version of sildenafil citrate for oral suspension 10 mg/mL. The drug is used to treat pulmonary arterial hypertension but may also be prescribed for other reasons. According to a company statement, IQVIA estimated annual sales for the 12 months that ended September 30, 2019, to be

$180 million. Common adverse effects include dyspepsia, flushing, headache, and visual disturbance.

FOR MORE INFORMATION: amneal.com

ADAPALENE AND BENZOYL PEROXIDE GEL

MARKETED BY: Glenmark

COMPARE TO: Epiduo

A generic version of Galderma’s Epiduo Gel will soon hit the market in a dosage strength of 0.1%/2.5%. The gel is indicated for the treatment of acute acne. A company statement cited sales data from IQVIA, which said that Epiduo Gel achieved annual sales of about $33.7 million in the 12-month period ended September 30, 2019. Common adverse effects of the gel include a burning sensation on the skin where applied, desquamation, erythema or stinging of the skin, and xerodema.

FOR MORE INFORMATION: glenmarkpharma.com

AMINOCAPROIC ACID TABLETS USP, 500 MG

MARKETED BY: Amneal Pharmaceuticals

COMPARE TO: Amicar

Amneal has received final FDA approval for generic aminocaproic acid tablets USP, 500 mg, indicated to prevent or treat bleeding. The drug functions by blocking the binding of plasminogen to fibrin and the subsequent conversion to plasmin. IQVIA estimated the US market annual sales for the drug for the 12 months ended September 30, 2019, at $23 million. In a company statement, Amneal said that it has immediately initiated commercialization activities.

FOR MORE INFORMATION: amneal.com

SUCRALFATE ORAL SUSPENSION

MARKETED BY: Amneal Pharmaceuticals

COMPARE TO: Carafate

The generic oral suspension, approved in a 1 g/10 mL dose, is an antacid indicated for the treatment of ulcers. It functions mainly by coating ulcer sites in the lining of the stomach and protecting them from acids, bile salts, and enzymes. It is indicated only for the short-term (<8 weeks) treatment of an active duodenal ulcer, and it should only be administered orally. Constipation is the most frequently reported adverse reaction, reported in about 2% of clinical trial participants. Amneal has immediately initiated commercialization activities.

FOR MORE INFORMATION: amneal.com